Get the Stockscreener App
248.08
0.73%
-1.83
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $248.08, with a volume of 5.42M.
It is down -0.73% in the last 24 hours and up +10.28% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$249.91
Open:
$251.005
24h Volume:
5.42M
Relative Volume:
0.78
Market Cap:
$438.31B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
122.36
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
-4.98%
1M Performance:
+10.28%
6M Performance:
+12.72%
1Y Performance:
+27.22%
1-Day Range:
$245.05
$251.66
1-Week Range:
$245.05
$260.92
52-Week Range:
$184.63
$261.63
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
248.08 | 438.31B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,188.58 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 618.61B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
123.54 | 305.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 293.94B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Eli Lilly & Co (LLY) - The Globe and Mail
BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $276 - Moomoo
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100 - GuruFocus
West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business - Yahoo Finance UK
ABBV Maintained by B of A Securities -- Price Target Raised to $276 - GuruFocus
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner - AOL.com
AbbVie Inc. Stock 12‑Month Price Target Raised to $263.72, Implies 6% Upside - TradingView
Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands - Investorideas.com
ABBV Maintains Overweight Rating -- Price Target Raised to $295 - GuruFocus
BofA Securities Adjusts AbbVie Price Target to $276 From $234 - marketscreener.com
ABBV Maintained by RBC Capital -- Price Target Raises to $260 - GuruFocus
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $276 to $295 - Moomoo
AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says - marketscreener.com
Dividend Roundup: Costco, Phillips 66, Abbott Labs, AbbVie, and more (DVY:NASDAQ) - Seeking Alpha
RBC Raises Price Target on AbbVie to $280 From $260, Keeps Outperform Rating - marketscreener.com
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie (NYSE:ABBV): Dividend Stability Under The Spotlight - Kalkine Media
JPMorgan Adjusts Price Target on AbbVie to $280 From $260 - marketscreener.com
ABBV Maintains Buy Rating -- Price Target Raised to $261 - GuruFocus
ABBV Maintained by JP Morgan -- Price Target Raised to $280 - GuruFocus
ABBV Leads Its Peer Group. You Pay For That - Trefis
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth - TradingView
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? - The Motley Fool
AbbVie stock trades steadily as investors weigh immunology and oncology pipeline - AD HOC NEWS
Guggenheim raises Abbvie stock price target to $261 on Rinvoq strength - Investing.com Canada
Guggenheim Adjusts Price Target on AbbVie to $261 From $249 - marketscreener.com
AbbVie Stock Traded Its Old Story for New Growth. Here Is The Price. - Trefis
AbbVie (NYSE:ABBV) Dividend Streak Gains Fresh Market Focus - Kalkine Media
AbbVie (ABBV) Wins EU Approval For Tepkinly, Is The Stock Fully Valued? - simplywall.st
AbbVie accused of hiding painful lump risk from Juvederm patients in new lawsuit - Claim Depot
ABBV Stock Quote Price and Forecast - CNN
AbbVie Stock Traded Its Old Story For New Growth. Here Is The Price. - Trefis
AbbVie Earnings Preview: What to Expect - Yahoo Finance
AbbVie Inc. outlines long-term growth drivers as a major biopharma player - AD HOC NEWS
More Than 2.5 Million Generic Prednisolone Acetate Eye Drops Recalled - Optometry Advisor
AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years - Barchart.com
AbbVie (NYSE:ABBV) Turns Rotation Into A Growth Story - Kalkine Media
AbbVie (ABBV) Expands Tepkinly Label for Follicular Lymphoma Tre - GuruFocus
AbbVie, Genmab granted EU label expansion for Tepkinly in follicular lymphoma - Seeking Alpha
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List) - Yahoo Finance
Global markets live: Broadcom, Meta, Walmart, Intel, AbbVie… - marketscreener.com
Scotiabank Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280 - Moomoo
EC approves AbbVie’s Tepkinly combination for follicular lymphoma - Pharmaceutical Business review -
AbbVie Inc. outlines long-term growth strategy as a major biopharma player - AD HOC NEWS
AbbVie (ABBV) Lowers Q2 Earnings Guidance Amid IPR&D Expenses - GuruFocus
AbbVie (ABBV) Anticipates Earnings Impact from IPR&D Expenses - GuruFocus
AbbVie revises guidance; expects Q2 EPS to include unfavorable impact of $0.17 - MSN
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
AbbVie (ABBV) Receives EU Approval for TEPKINLY in Follicular Ly - GuruFocus
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.22%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):